No photo of Paul F. Riska

View Scopus Profile

Paul F. Riska, M.D.

  • 989 Citations
  • 16 h-Index
1989 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Paul F. Riska is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles
Mycobacterium tuberculosis Medicine & Life Sciences
Luciferases Medicine & Life Sciences
Mycobacteriophages Medicine & Life Sciences
Bacteriophages Medicine & Life Sciences
Clostridium difficile Medicine & Life Sciences
Clostridium Infections Medicine & Life Sciences
Mycobacterium Medicine & Life Sciences
Anti-Bacterial Agents Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 1998 2004

MYCOBACTERIOPHANGE INTERACTION WITH M TUBERCULOSIS

Riska, P. F.

National Institutes of Health

7/15/98 → 6/30/04

Project: Research project

Mycobacterium
Tuberculosis
Bacteriophages
Molecular Biology
Mycobacteriophages

Publications 1989 2019

  • 989 Citations
  • 16 h-Index
  • 29 Article
  • 1 Conference contribution

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

INSIGHT FLU-IVIG Study Group, Nov 2019, In : The Lancet Respiratory Medicine. 7, 11, p. 951-963 13 p.

Research output: Contribution to journal › Article

Open Access
Intravenous Immunoglobulins
Human Influenza
Randomized Controlled Trials
Placebos
Infection
9 Citations (Scopus)

Effect of algorithm-based therapy vs usual care on clinical success and serious adverse events in patients with staphylococcal bacteremia a randomized clinical trial

the Staphylococcal Bacteremia Investigators, Sep 25 2018, In : JAMA - Journal of the American Medical Association. 320, 12, p. 1249-1258 10 p.

Research output: Contribution to journal › Article

Bacteremia
Randomized Controlled Trials
Therapeutics
Anti-Bacterial Agents
Coagulase
1 Citation (Scopus)

Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study

For the INSIGHT FLU003 Plus Study Group, Jan 1 2018, In : Open Forum Infectious Diseases. 5, 1, ofx228.

Research output: Contribution to journal › Article

Indoleamine-Pyrrole 2,3,-Dioxygenase
Human Influenza
Disease Progression
Tryptophan
Kynurenine
1 Citation (Scopus)

Two for the price of one: Emerging carbapenemases in a returning traveller to New York City

Mittal, J., Szymczak, W. A., Guo, Y., Levi, M. H., Chen, L., Kreiswirth, B. N., Riska, P. F. & Nori, P., Jan 1 2018, In : BMJ Case Reports. 2018, bcr-2018-225440.

Research output: Contribution to journal › Article

Carbapenems
Bangladesh
Enterobacteriaceae Infections
Aztreonam
Klebsiella pneumoniae
41 Citations (Scopus)

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

CoDIFy study group, Jul 1 2017, In : The Lancet Infectious Diseases. 17, 7, p. 735-744 10 p.

Research output: Contribution to journal › Article

Clostridium Infections
Clostridium difficile
Vancomycin
Safety
Therapeutics